Cargando…

Both cladribine and alemtuzumab may effect MS via B-cell depletion

OBJECTIVE: To understand the efficacy of cladribine (CLAD) treatment in MS through analysis of lymphocyte subsets collected, but not reported, in the pivotal phase III trials of cladribine and alemtuzumab induction therapies. METHODS: The regulatory submissions of the CLAD Tablets Treating Multiple...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baker, David, Herrod, Samuel S., Alvarez-Gonzalez, Cesar, Zalewski, Lukasz, Albor, Christo, Schmierer, Klaus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5459792/ https://www.ncbi.nlm.nih.gov/pubmed/28626781 http://dx.doi.org/10.1212/NXI.0000000000000360

Ejemplares similares

Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis
por: Afolabi, Dayo, et al.
Publicado: (2017)

CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis
por: Baker, David, et al.
Publicado: (2022)

Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?
por: Mao, Zhifeng, et al.
Publicado: (2018)

Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells
por: Ceronie, Bryan, et al.
Publicado: (2018)

Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis
por: Alvarez‐Gonzalez, Cesar, et al.
Publicado: (2017)

Detecting and predicting neutralization of alemtuzumab responses in MS
por: Saxena, Gauri, et al.
Publicado: (2020)

Alemtuzumab/cladribine/natalizumab: Lymphopenia and COVID-19 infection: case report
Publicado: (2021)

Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets: A MAGNIFY-MS Substudy
por: Wiendl, Heinz, et al.
Publicado: (2022)

No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine
por: Pakpoor, Julia, et al.
Publicado: (2015)

A cell-based assay for the detection of neutralizing antibodies against alemtuzumab
por: Ali, Liaqat, et al.
Publicado: (2020)

Mitigating alemtuzumab-associated autoimmunity in MS: A “whack-a-mole” B-cell depletion strategy
por: Meltzer, Ethan, et al.
Publicado: (2020)

Cladribine Tablets: A Review in Relapsing MS
por: Deeks, Emma D.
Publicado: (2018)

Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis
por: Schmierer, Klaus, et al.
Publicado: (2022)

Severe lymphopenia after subcutaneous cladribine in a patient with multiple sclerosis: To vaccinate or not?
por: Mateo-Casas, M., et al.
Publicado: (2020)

Vitamin D supplementation for the prevention or depletion of side effects of therapy with alemtuzumab in multiple sclerosis
por: Goischke, Hans-Klaus
Publicado: (2019)

The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies
por: Baker, David, et al.
Publicado: (2020)

Correction to: Cladribine Tablets: A Review in Relapsing MS
por: Deeks, Emma D.
Publicado: (2019)

Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS
por: de Stefano, Nicola, et al.
Publicado: (2022)

Case of alemtuzumab-related alopecia areata management in MS
por: Chan, Jillian K., et al.
Publicado: (2018)

Emerging safety issues in alemtuzumab-treated MS patients
por: Killestein, Joep, et al.
Publicado: (2019)

Can We Improve the Monitoring of People With Multiple Sclerosis Using Simple Tools, Data Sharing, and Patient Engagement?
por: Allen-Philbey, Kimberley, et al.
Publicado: (2020)

Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients
por: Allen-Philbey, Kimberley, et al.
Publicado: (2021)

Alemtuzumab: COVID-19 infection and severe depletion of T-lymphocyte: case report
Publicado: (2020)

Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management
por: Cuker, Adam, et al.
Publicado: (2019)

Microscopic polyangiitis after alemtuzumab treatment in relapsing-remitting MS
por: Sauer, Eva-Maria, et al.
Publicado: (2018)

Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis
por: Allen-Philbey, Kimberley, et al.
Publicado: (2023)

A Model-Based Economic Evaluation of Cladribine Versus Alemtuzumab, Ocrelizumab and Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis with High Disease Activity in Chile
por: Espinoza, Manuel Antonio, et al.
Publicado: (2021)

Alemtuzumab
por: Tridente, Giuseppe
Publicado: (2013)

Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies
por: Dayan, Colin M., et al.
Publicado: (2023)

Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS
por: Thomas, Katja, et al.
Publicado: (2016)

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
por: Giovannoni, Gavin, et al.
Publicado: (2016)

Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD study
por: Montalban, Xavier, et al.
Publicado: (2018)

CD52-targeted depletion by Alemtuzumab ameliorates allergic airway hyperreactivity and lung inflammation
por: Shafiei-Jahani, Pedram, et al.
Publicado: (2021)

Cladribine vs other drugs in MS: Merging randomized trial with real-life data
por: Signori, Alessio, et al.
Publicado: (2020)

Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine
por: Seferoğlu, Meral, et al.
Publicado: (2021)

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS
por: Rolfes, Leoni, et al.
Publicado: (2019)

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy
por: Havrdova, Eva, et al.
Publicado: (2017)

Long‐term peripheral immune cell profiling reveals further targets of oral cladribine in MS
por: Moser, Tobias, et al.
Publicado: (2020)

Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS
por: Arnold, Douglas L., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_pgpc1qolqi8rcgc3elqiivig1u